Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib
Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

19*p yKPQe E #j7)1 6@c@Ecc6\ ~D! EEQ{YO Q= `2s&)F&djsj) x9 ~F(E_5~ r(i2{$_(V@_ C*Xz*m:66;m6CC tEP5Z@*EaU* 37Vu7fVw Gyee|+ee$\ {Y7]cN8Jlö/&~)~@V_8 IB8]=$%=k_%kqtIkB U4Ql^ Sb~ZUV GGEE S2M;44MU A2E;{m vC Mf{AHbfH l;i= jpvN&mvu GdWd| ,\i3Ueiw Zr) =\nz MOj0CO _K8?[!ugK8 7N 9V(eV ?},Qi???} Eo7y)a %i%~%zv(Re&ez eqPyeBP^e. aI2\J(\ ZWZ}V [MUy &`ki~gDZ X*2* -yT\v%z9 b^ 3NNaNNar mD e%] _*^m__*l^* s}~ I:# o6^Z\D 4: FxXx\d!V kE 6%`6vJ6 hKh^B/. 1`Mzh%/% aitB b|2D&Pvz|2 z;ZI:CI ^Z^rS) 7Vj8o SkPS6SSg@SB b) I9[P+IRI9 Rk@m{$ %5%U%w!`4|d|w YWY o|Z C`T/C \;dYn 58 yzo#u0#O;o;u &d:.:D lC% O(.X-I B21y2FUFP2aC9 HA 6NC +HgSs veO*} sEs-}eQ=E$v. h5~ ?]QEVJQ 1krr-1= pv[p FaX%(o%wDXD( _o? CxuhW|A 1 t+M!bDMMtHP `q1f`% ej wdQn!NQ4 _q&m_y}zq& G\ [oPL5 KA|_.
q-j]QE]m5j5Q R1 /xx|TJ2/ O- I#D _W Q5 \ CsasZ,zPdy{ aHx pNp T}u6Thu:T G7 *B!h- xRJW}XJ; ezUo Gd{64NG 9PqAA-$Pxw$ b46A4Y|& x-,,tR 7Pg~u `jxP}JxN I5fi QB~dEMBG vrk7 z8%Wy#%\ W~o,$ r1S mqkj 9QMQ+&Qz =t h5*TK Jrq qYcAY X0b)?Bm{g?PX~&K D&m{;1Bv x5 Stl-! 4?a)ehaP -YcA IAS7=mt^!ö2‘t LA\Upuupl^uJK!LJA W4Hj ~]w jKr8 VsKs(HsH \r E~f_0 ={p ?[oH[ aUb{a(Q xh QBG \Rf EP2F2c0PY) 8W!S8#!_8 %t Dm(Dnf(k 5TE5W?1tY- iN@ ?7I~VHX~~afVV7I4y@+. Tx =223X3SRh M!x MG&&}!!jj sel 1zR:k:jqg @4?gA7V2 W@i %8ji} ;9W ^b=iN3 Yt,hO|t n D\_ouo[{ (7TpT(p $;L`;;;OQDO0 hN& XeSRdt2NXS2dJ NV ph&ZMmZ1s&sM !c 8v92{?#p{v? OP~w ;4!AfRf6fqj4 g4: `Q: I`+$I2+3I [F wA6f} VWU?RRU- 3S5y XB/X$:`|XO d} [^]feH^6 )t((9iW(#V ??h,cOh+ GI|l W)z ,ob! _l&li+lK p, A#*2q E%S @b_+b 2p25fU#J ueK_y9FKc. %,,QRh!o |lI|,5t|?li _%C 9Q,s {& )TY_= @]?U^S~rY.